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Abstract
Purpose Until recently, surgery was the only remaining
choice for moderate to severe chronic ulcerative colitis pa-
tients who failed standard treatment or when it was not toler-
ated. Anti-TNFα treatment is a new, non-invasive option for
the management of ulcerative colitis. The objective of this
study was to assess the cost-effectiveness of induction and
maintenance treatment up to 1 year of ulcerative colitis with
adalimumab/standard care and standard care alone in Poland.
Methods A Markov model was used to estimate the expected
costs and effects of adalimumab/standard care and a standard
care alone. For each treatment option, the costs and quality
adjusted life years were calculated to estimate the incremental
cost-utility ratio. The analysis was performed from the per-
spective of the Polish public payer and society over a 30-
year time horizon. Different direct and indirect costs and util-
ity values were assigned to the various model health states.
Results The treatment of ulcerative colitis patients with
adalimumab/standard care up to 1 year instead of a standard
care alone resulted in 0.14 additional years of life with full
health (QALYs). The incremental cost-utility ratio of
adalimumab/standard care compared to the standard care
alone is estimated to be 76,120 €/QALY gained from NHF
perspective and 71,457 €/QALY gained from social
perspective.
Conclusions The biologic treatment of ulcerative colitis
patients with adalimumab/standard care is more effective but
also more costly compared with standard care alone.
Keywords Ulcerative colitis . Cost-utility . Adalimumab .
Economic analysis . Indirect costs
Introduction
Ulcerative colitis (UC) is an idiopathic inflammatory bowel
disorder characterized by an inflammatory reaction involving
the colonic mucosa [1, 2]. The clinical course is unpredictable
and marked by alternating periods of exacerbation and remis-
sion, which may occur spontaneously or in response to treat-
ment changes or intercurrent illnesses [3, 4]. Although prog-
ress has been made in the overall management of the disease,
no medical cure has been discovered [5].
The introduction of anti-tumor necrosis factor-alpha (anti-
TNFα) treatment allowed a new option for the management of
ulcerative colitis and is expected to decrease the rate of
colectomies or at least to extend the time to surgery, compared
with standard treatment. Adalimumab/standard care superior
efficacy compared to standard care alone in moderate to se-
vere non-acute UC has been well established by the clinical
trials [6, 7]. On the other hand, the use of biologics constitutes
a heavy burden for the public payer, so its usage can be limited
in many countries.
In Poland, patients with severe UC who are not able
to have cyclosporine therapy and do not respond to
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standard care have the possibility to receive the induction
treatment with infliximab, which consists of three admin-
istrations of the drug. At present, there is no biological
maintenance treatment of ulcerative colitis reimbursed in
Poland, hence patients often lose their response or remis-
sion, which were achieved during the induction phase.
Additionally, the lack of biological maintenance treat-
ment leads to an increased rate of colectomies.
Adalimumab, nor any other biologic therapy, is not re-
imbursed from public funds in UC treatment at all. In
this connection, there was a need for economic evalua-
tion of UC induction and maintenance therapy with a
TNFα inhibitor at Polish settings.
This study uses an economic evaluation to assess the cost-
effectiveness of induction and maintenance treatment up to
1 year of ulcerative colitis with adalimumab/standard care
and standard care alone in Poland.
Methods
Overview
AMarkov model was used to estimate the expected costs and
effects of adalimumab/standard care and standard care alone
used in the induction and maintenance treatment of moderate
to severe ulcerative colitis (model structure, inputs, transition
probabilities, costs of health states, and utilities are presented
in Fig. 1, Tables 1 and 2). For each treatment option, the costs
and quality adjusted life years (QALYs) were calculated to
estimate the incremental cost-utility ratio (ICUR). The analy-
sis was taken from the perspective of the Polish public payer
and also from expanded social perspective (indirect costs in-
cluded). Ulcerative colitis could be a lifelong disease, which is
why the 30-year time horizon was selected for the base-case
analysis. Costs and outcomes were discounted at an annual
rate of 5 and 3.5 %, respectively.
The target population consists of a hypothetical cohort
of adult patients with moderately to severely active ul-
cerative colitis, despite concurrent therapy with steroids
and/or azathioprine or 6-mercaptopurine. The average
weight and age of a patient was 75.37 kg (range:
73.60–77.14) and 39.60 years (95 % CI: 38.05–41.15),
respectively, and the percentage of women was 42.7 %
(95 % CI: 35.6–45.5 %). This was based upon baseline
data from the reference clinical trial ulcerative colitis
long-term remission and maintenance with adalimumab
2 (ULTRA 2) [6]. Based on the current practice and
reference clinical trial, in the model adalimumab was
assumed to be administered in a dose of 160 mg at week
0, 80 mg at week 2, and 40 mg every other week begin-
ning at week 4 up to 1 year [6, 7].
Model structure
The modeling was carried out based on a Markov-type
cohort simulation process and implemented in Microsoft
Excel 2007 with Visual Basic for Applications tool
(Microsoft Corporation, Redmond, WA). The patient en-
ters this model when starting the induction treatment.
The time horizon is divided into two periods: from
week 0 to 8 (period 1; induction treatment) and the
weeks from nine (period 2; maintenance treatment).
The cycle length during period 1 is 1 week, and cycles
in period 2 last 8 weeks. After the ninth cycle, the
response to induction therapy and remission was
assessed and biological treatment was continued only
in responders (patients who responded or experienced
remission). Mayo score was used to assess the UC ac-
tivity (scores can range from 0 to 12, with higher scores
indicating more severe disease activity): values from 0
to 2 means remission, 3–5 mild disease, 6–12 moderate-
severe disease [6]. The clinical response was defined as
a decrease from the baseline in the total Mayo score by
at least 3 points and at least 30 %, with an accompa-
nying decrease in rectal bleeding subscore of at least 1
point or an absolute rectal bleeding subscore of 0 or 1.
Clinical remission was defined as a total Mayo score of
2 points or lower, with no individual subscore exceed-
ing 1 point [6]. In accordance with Polish clinical prac-
tice, for standard care, it is assumed that in both the
induction and maintenance phases, 100 % of patients
have both corticosteroids and aminosalicylates, 80 %
have mercaptopurine, and 20 % have azathioprine.
Patients who have neither remission nor response to induc-
tion treatment with the TNFα inhibitor/standard care or stan-
dard care alone will stop the treatment, move to an active
disease state and start standard care alone or will have a
colectomy. If one of the treatments (adalimumab/standard care
or standard care alone) led to a clinical response or remission,
the patient continued with the treatment in the maintenance
phase.
Maintenance treatment with adalimumab is restricted to
1 year in base-case analysis and no limitation for biolog-
ical treatment was assumed in sensitivity analysis
(adalimumab administered until loss of response or death,
according to what occurs first). Patients who experienced
the response or remission can sustain or lose it during the
next cycle. The treatment can be discontinued when un-
acceptable adverse events occur; in this case, the patient
moves to a standard care alone state. Patients who failed
adalimumab/standard care or standard care alone treat-
ment continued standard care in the maintenance phase,
but they could have a colectomy if their disease remained
active. Patients can experience remission or response dur-
ing standard care, the same as during standard care alone
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treatment. Standard care is continued regardless of wheth-
er the patient has remission, response, or is in an active
disease state. All patients who had a colectomy can expe-
rience temporary complications and finally achieve
clinical remission after surgery (see: Fig. 1.). It was as-
sumed that all complications occur immediately after sur-
gery (in the same cycle) and are resolved during the 8-
week period.
Figure 1 Structure of Markov model for patients with UC. The cycle
length during induction phase is 1 week, from week 9, it is 8 weeks. All
complications after surgery (state 10.) are assumed to be temporary and
resolved during the 8-week period. It was assumed that the probability of
death will be the same for each clinical state. ADA adalimumab, SoC
standard of care
Table 1 Clinical inputs and utilities





Response rate—8 week Adalimumab/standard care (RR) 1.34 1.02 1.77 [6]
Standard care alone 0.25 0.20 0.31 [6]
Remission rate—8 week Adalimumab/standard care (RR) 1.77 1.10 2.86 [6]
Standard care alone 0.09 0.06 0.13 [6]
The probability of response per cycle—
52 week
Standard care alone 0.016 0.010 0.023 [6]
Response per cycle—52 week (RR) Adalimumab/standard care 1.32 0.80 2.18 [6]
The probability of remission per cycle—
52 week
Standard care alone 0.014 0.009 0.020 [6]
Remission per cycle—52 week (RR) Adalimumab/standard care 2.03 1.24 3.32 [6]
The probability of response loss per cycle—
8–52 weeks
Adalimumab/standard care 0.161 – – [6]
Standard care alone 0.158 – – [6]
The probability of remission loss per cycle—
8–52 weeks
Adalimumab/standard care 0.000 – – [6]
Standard care alone 0.016 – – [6]
The probability of complications after
surgery
0.53 0.27 0.53 [11]
Surgery rate per cycle Adalimumab/standard care (RR) 0.77 0.33 1.86 [10]
Standard care alone 0.75 % – – [10]
Utilities Active treatment 0.420 0.320 – [12, 13]
Remission 0.880 0.790 0.910 12, 13]
Response 0.760 0.580 0.940 [12]
Remission after surgery 0.610 – – [12]
Complications after surgery 0.420 – 0.490 [12, 13]
RR relative risk, LCI lower confidence interval, UCI upper confidence interval
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Certain adverse events were not included in the model. In
accordance with reference clinical trial [6], adalimumab treat-
ment was generally well tolerated and the overall safety pro-
file of adalimumab was comparable with that of placebo. A
similar proportion of patients in each study group experienced
treatment emergent adverse events, which were nonserious,
mild, or moderate in severity, and were considered not related
or probably not related to study drug [6].
There is no evidence that patients with UC have lower life
expectancy; thus, the probability of death was calculated on a
basis of life expectancy table for general Polish population
(www.stat.gov.pl). It was assumed that the probability of
death will be the same for each clinical state. No data was
found on the different probability of death from particular
clinical states of model for natural course of the disease.
Clinical inputs
Transition probabilities in the model were calculated based on
the response, remission rates, and discontinuation due to ad-
verse event rates which came from randomized, double-blind,
placebo-controlled trial. The ULTRA 2 study evaluated the
efficacy of adalimumab in induction and maintenance of clin-
ical remission in patients with moderate to severe ulcerative
colitis who received concurrent treatment with oral corticoste-
roids or immunosuppressants [6]. As the definitions of remis-
sion and response were overlapping in ULTRA 2 study [6],
responders from this analysis excluded those who achieved
remission. The above provides the separation of these two
states in a model.
In ULTRA 2 study, the effectiveness was assessed at
week 8 (after induction treatment), at week 32, and at
week 52 (maintenance treatment; data available only for
week 8 and week 52 [6]). Transition probabilities for
adalimumab/standard care after discontinuation of the
biological treatment were assumed to be the same as
for the standard care alone arm. Clinical parameters
and utility values used in the model are presented in
Table 1.
A proportion of non-responders to medical treatment
underwent surgery. To derive the probability of
colectomy, we used the data from the study by Feagan
et al. [12] estimating that during the 52-week period,
3.68 % (15 per 408.1 patient-years) and 4.75 % (11 per
231.7 patient-years) of patients treated with adalimumab/
standard care and standard care alone have a colectomy,
respectively. Using the above data as our basis, we cal-
culated the probability of a colectomy in 1 cycle
(Table 1).
Patients undergoing surgery either achieved post-
surgery remission and maintained it through the whole
time horizon or suffered from immediate post-surgery
complications, which were assumed to occur during the
same cycle as surgery and resolved in 8-week period.
The probability of surgery complications was calculated
based on the study by Arai et al. [9] and Fazio et al. [8]
(Table 1). After resolving the complications within the 8-
week period, it was assumed that patients achieve post-
surgical remission, just as patients who did not experi-
ence any complications.
Table 2 Cost inputs
Parameter Mean 95 % LCI 95 % UCI Reference
Drug cost [PLN] Adalimumab 1 mg 54.55 – – Decree of the Minister of Health
Azathioprine 1 mg 0.0107 – –
Prednisolone 1 mg 0.1055 – –
Mesalazine 1 mg 0.0015 – –
Mercaptopurine 1 mg 0.0166 – –
Monitoring costs per cycle [PLN] 8 weeks cycle 121.56 – – Expert opinion, decree of the
President of NHF1 week cycle 15.20 – –
Administration costs [PLN] 468.00 – – Expert opinion, decree of the
President of NHF




4160 – – Expert opinion, decree of the
President of NHF
Standard treatment per cycle [PLN] 8 weeks cycle 204.32 – – Decree of the Minister of Health;
expert opinion1 week cycle 25.54 – –
Indirect costs [PLN/year] Remission 6523.75 – – Data unpublished
Active disease 22,934.58 – –
€1 = 4.2 PLN, based on the average exchange course from the year 2015
PLN Polish zloty, NHF National Health Fund
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Costs
Costs were considered from a national health system (National
Health Fund, NHF) perspective and from social perspective,
and therefore, direct medical and indirect costs were included.
The costs were presented in 2015 Polish zloty (PLN), and the
results were presented in Euros (€; €1 = 4.2 PLN). Direct
medical costs considered in the model included those related
to initiation and maintenance treatment with adalimumab
(drug and administration costs), standard care, monitoring
and hospitalization costs, surgery costs, and treatment of com-
plications after surgery costs.
The costs of drugs used in the study population are based
on the actual unit prices of reimbursement medical products.
Table 2 presents all drugs’ unit costs. The dosage of drugs
used in standard care, as well as monitoring costs was deter-
mined by expert opinion.
Indirect costs come from study carried out in Poland on 202
patients with UC (unpublished). They include absenteeism,
presenteeism, and costs of leaving earlier the labor market,
separately for remitted patients and those with active disease.
Indirect costs generated by patients in remission were
assigned to responders (patients with respond or remission),
and indirect costs generated by patients with active disease
were assigned to the rest.
Utilities and quality of life
A systematic reviewwas made to identify the utility values for
different health states in the model. After analysis of the avail-
able data, we chose the values presented by Woehl et al. [10]
because this study is the most useful for source utility values
of different stages included in the model; it reported EQ-5D
utility values and was carried out on 18,573 patients from the
UK (Table 1). The utility values were reported for following
states: remitting disease, mild disease, and moderate to severe
disease. These categories of disease severity were based on the
simple colitis activity index. We assumed that the utility value
for moderate to severe disease that responded to treatment was
equal to the value for mildly active disease by Woehl et al.
[10]. In patients during the treatment or who are in an active
disease state or had complications after surgery, the utility
value was assumed to be as in active moderate to severe dis-
ease. We assumed that in the post-surgery remission state, the
utility value would be lower than that in the remission after the
treatment state, which reflects the effect of chronic complica-
tions after a colectomy on the patient’s quality of life. All
utility values are presented in Table 1.
An alternative set of utility values was used in the sensitiv-
ity analyses, based on the study by Arseneau et al. [11]. There
was no change in the sensitivity analyses in utility value for
remission after surgery state; to all other states, different utility
values were assigned and are presented in Table 1.
Economic analysis
The primary outcome of this simulation study was the ICUR
of the treatment with adalimumab/standard care and the stan-
dard care alone, expressed as an incremental cost per QALY
saved. The ICUR was calculated by dividing the difference in
total costs (from the public payer’s and social perspective) by
the difference in effectiveness in QALYs between
adalimumab/standard care and standard care alone.
Sensitivity analysis
Sensitivity analyses to evaluate the robustness of our findings
were conducted. Variability of cost-effectiveness results ac-
cording to the change of key variables was assessed using
one-way sensitivity analysis. Values used in sensitivity analy-
sis for clinical, cost, and utility parameters are presented in
Table 1 and 2. Parameter uncertainty was evaluated using
probabilistic sensitivity analysis (PSA).
Results
Base-case analysis
The results of the base-case analysis are presented in Table 3.
The treatment of UC patients with adalimumab/standard care
instead of the standard care alone resulted in 0.140 additional
years of life in full health.
The treatment with adalimumab/standard care was found to
be more expensive than treatment with the standard care alone
from the NHF perspective by €10,647 and from the social
perspective by €9995. The incremental cost per QALY gained
was €76,120 from NHF perspective and €71,457 from social
perspective (Table 3.).
Sensitivity analysis
Results of various one-way sensitivity analyses are presented
in Supplementary materials. The range of ICUR values ob-
tained during the one-way sensitivity analysis was from
38,924 €/QALYG to 265,081 €/QALYG from NHF perspec-
tive and from 34,244 €/QALYG to 260,504 €/QALYG from
social perspective. Biological treatment with no time restric-
tion (until disease progression, i.e. lose of response, or death)
resulted in ICUR value equals 97,672 €/QALYG from NHF
perspective and 92,448 €/QALYG from social perspective.
The difference in QALY between adalimumab/standard care
and standard care alone was 0,480 with assumption of no time
limitation of biological treatment.
The results of the PSA, testing the whole range of all the
uncertain parameters, are presented as a cost-effectiveness ac-
ceptability curve (Fig. 2). The mean ICUR and the 95 %
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confidence interval for adalimumab/standard care when com-
pared to the standard care alone was 73,909 €/QALYG, 95 %
CI: 56,745–107,058 from the public payer’s perspective and
69,270 €/QALYG, 95 % CI: 52,132–102,190 from social per-
spective. The results of the PSA suggest adalimumab/standard
care to be cost-effective with a WTP equals about €73,800.
Discussion
Using a 30-year time horizon and the restriction for the duration
of TNFα inhibitor therapy to 1 year, adalimumab/standard care
treatment turned out to bemore effective andmore costly option
compared with the standard care alone in Poland. One year bio-
logic treatment provided an ICUR value of 71,457–76,120
€/QALYG, depending on the perspective. Biologic treatment
came to be more effective but less cost-effective for the public
payer and society when there is no restriction for treatment
duration.
The present economicmodel is the first studywhich assesses
the biological maintenance treatment of UC in Poland and is the
first study which included indirect costs of the disease.We used
the data from randomized clinical trial to assess the effectiveness
of biological treatment, as there is no data concerned Polish pa-
tients. Such a model can offer support to the decision makers as
long as it reflects real-world conditions.
Even though the present study evaluated the cost-
effectiveness of adalimumab in the Polish setting, the results
could be adopted by the healthcare system in other countries.
To use this economic evaluation in other country, it should be
checked: (1) if the patients’ characteristics are similar, (2) if
the comparator corresponds to the clinical practice in this
country, and (3) if the treatment pattern is similar [13].
Additionally, the country-specific costs of drug and medical
procedures should be included.
In our analysis, we did not include mortality due to UC
because there is an evidence which indicates that patients with
UC have normal life expectancy, subsequently, meaning that
treatment will not influence the survival. Additionally, mortal-
ity was not an outcome in the reference clinical study. We also
did not include treatment-related adverse events, as they have
a relatively small impact on the cost and quality of life. Some
assumptions had to be made concerning the utility values. The
utility value for mildly active disease was assigned to patients
who responded to treatment, while in patients who had com-
plications after surgery, the utility value was assumed to be as
that in active moderate to severe disease.
A systematic review by Xie carried out in October 2014 was
found, concerned the economics of adalimumab for ulcerative
Table 3 Base-case results






QALY 15.204 15.064 0.140
Total direct costs - public payer perspectivea €20,598 €9950 €10,647
Adalimumab costsb €10,550 €0 €10,550
Standard care costs €5328 €5247 €82
Monitoring costs €3196 €3149 €47
Colectomy costs €1523 €1555 €-32
Total indirect costs €73,168 €73,820 €-652
Total direct and indirect costs - social perspectivec €93,765 €83,770 €9995
ICUR - public payer perspective 76,120 €/QALYG
ICUR - social perspective 71,457 €/QALYG
€1 = 4.2 PLN, based on the average exchange course from the year 2015
€ euro
a Total direct costs include: pharmacotherapy costs (biological treatment), standard care costs, monitoring costs,
adalimumab administration costs, colectomy and complications after surgery costs
b Drug and administration costs
c Total indirect costs included absenteeism, presenteeism, cost of early leaving the labor market
Fig. 2 Cost-effectiveness acceptability curve showing the probability
that adalimumab with standard care is cost-effective vs. standard care
alone at a range of different threshold values
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colitis [14]. Author identified three economic analysis for




form of ICUR values, which were for adalimumab vs. standard
care£96,733and£22,087over1-year and5-yearhorizons (2010
values), respectively. It was impossible to compare the results of
above study with ours as limited information about the model
inputs, assumptions, and structure is provided in the abstract.We
also performed our own review of published economic analysis
for study subject. We found two additional studies for
adalimumab/standard care compared with standard care alone
inUC.Bothstudieswerepresented ina formofabstract; full texts
arenot available [16,17].Noresults concerning theeffectiveness
were presented. The ICUR values obtained in the above studies
for adalimumab/standard care vs. standard care alone were
C$96,812 over 5-year horizon (2013 values) [16] and €46,815
over 10-year horizon (2013 values) [17]. As in the case of previ-
ousstudy, it ishard tocompareour resultswith theabovebecause
only abstracts with limited information about methodology, in-
puts, andassumptionsareavailable.All threepublishedeconom-
ic analyses showed that adalimumab/standard care compared
with standard care alone inUC seems to be a cost-effective treat-
ment option. It is worth to mention that none of the identified
studies included indirect costs.
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